Should You Buy Terns Pharmaceuticals Inc (TERN) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
BUY right now. Despite a still-soft near-term technical setup (MACD below zero), TERN is trading near a defined support zone (~33.9–35.0) after a major re-rating, while Wall Street has aggressively raised targets into the mid/high-$50s on differentiated Phase 1 CARDINAL/ASH data for TERN-701. Options positioning also leans bullish (put/call ratios < 1). For an impatient buyer, the current post-market area (~35.25) is an acceptable entry point with upside skew driven primarily by continued clinical execution and expanding 1L/2L CML expectations.
Technical Analysis
Price/levels: Post-market ~35.25 sits just below the Pivot (35.706), with nearby support at S1=33.932 (then S2=32.836) and resistance at R1=37.481 (then R2=38.577). Momentum: MACD histogram is negative (-0.483) but 'negatively contracting' suggests downside momentum is fading (often consistent with basing). RSI(6)=38.69 is weak but not deeply oversold—consistent with a pullback/consolidation rather than an active uptrend. Moving averages are converging, signaling consolidation and a potential inflection zone rather than a clean trend. Practical read: near-term trend is neutral-to-slightly bearish, but price is close to support where rebounds commonly start if buyers step in.
Analyst Ratings and Price Target Trends
Recent trend is strongly positive: from mid/late Nov through Dec 2025, multiple firms reiterated Buy/Outperform/Overweight and raised targets sharply (e.g., Oppenheimer $28→$58, H.C. Wainwright $20→$60, Barclays $36→$56, Truist $35→$56, BMO $35→$54, Citizens $35→$57). Wall Street pros: best-in-class potential for TERN-701, strong efficacy + tolerability, and potential expansion into frontline CML; platform confidence. Wall Street cons: durability/follow-up length still a key variable (treatment duration data needed), and the valuation/expectations are now more sensitive to any future trial hiccups after the big move.
Wall Street analysts forecast TERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 53.75 USD with a low forecast of 35 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast TERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 53.75 USD with a low forecast of 35 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 34.200
Current: 34.200
